Berberis composition for cognitive health
US-2024424045-A1 · Dec 26, 2024 · US
US10335371B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10335371-B2 |
| Application number | US-201615551636-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 17, 2016 |
| Priority date | Feb 17, 2015 |
| Publication date | Jul 2, 2019 |
| Grant date | Jul 2, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to solid pharmaceutical dosage forms suitable for use as drinking water medication. More in particular, the present invention provides solid pharmaceutical dosage forms comprising a pharmaceutically active agent, a non-ionic surfactant having an Hydrophilic Lipophilic Balance (HLB) of at least 8, and a maltodextrin. The present invention also provides the use of such pharmaceutical dosage forms in veterinary medicine, more in particular as drinking water medication; as well as methods for preparing such pharmaceutical dosage forms.
Opening claim text (preview).
The invention claimed is: 1. A method for the preparation of a spray-dried solid pharmaceutical multiparticulate dosage form, the method comprising: preparing a suspension comprising a pharmaceutical non-solubilized active ingredient, a non-ionic surfactant having an Hydrophilic Lipophilic Balance (HLB) of at least 8 and water; milling the suspension; adding a maltodextrin to the milled suspension; and spray-drying the milled suspension. 2. The method according to claim 1 , wherein: the non-ionic surfactant has an HLB of 8 to 20; and the pharmaceutical non-solubilized active ingredient is selected from the group consisting of antibiotics, anticoccidials, and non-steroidal anti-inflammatory drugs. 3. The method according to claim 1 , wherein the pharmaceutical non-solubilized active ingredient is a poorly water-soluble active agent. 4. The method according to claim 1 , wherein the pharmaceutical non-solubilized active ingredient is selected from the group consisting of pyrimidine antibacterial chemotherapeutics, macrocylic lactones, anticoccidials, and non-steroidal anti-inflammatory drugs. 5. The method according to claim 1 , wherein the non-ionic surfactant is a polysorbate selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, and polysorbate 80. 6. The method according to claim 1 , wherein the maltodextrin is selected from the group consisting of maltodextrin with a Dextrose Equivalent (DE) of 9, maltodextrin with a DE of 14, and maltodextrin with a DE of 18.
Animal feeding-stuffs · CPC title
containing oxygen or sulfur as hetero atom · CPC title
Sugars; Polysaccharides · CPC title
Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006) · CPC title
for poultry · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.